-
Luoxin Pharmaceutical Subsidiary Omeprazole Sodium for Injection Passed the Consistency Evaluation
Time of Update: 2021-03-27
("Shandong Luoxin") had recently received the approval and issue of Ogilvy for Injection from the National Medical Products Administration.
The omeprazole sodium for injection developed by Shandong Luoxin was first approved for marketing in 2005.
-
Eli Lilly's antibody bamlanivimab is discontinued in three U.S. states
Time of Update: 2021-03-27
Previously, the US FDA had instructed Eli Lilly and its antibody development partner Regeneron to track virus mutations.
Eli Lilly's Covid-19 drug bamlanivimab is no longer distributed in 3 states because of a variant, Woodcock says2.
-
A pharmaceutical company was warned for failing to comply with GMP during the inspection process
Time of Update: 2021-03-27
Violation of "Pharmaceutical Production Quality Management Regulations"The on-site inspection of Fujian Minghua Pharmaceutical Co.
-
AstraZeneca announces the latest phase 3 clinical results of the new crown vaccine
Time of Update: 2021-03-27
The Data Safety Monitoring Committee found no increased risk of thrombosis in 21,583 subjects who received at least one dose of the vaccine, and no CVST event was found in this clinical trial.
-
Fuan Pharmaceutical: Cefminox sodium for injection passed the consistency evaluation
Time of Update: 2021-03-27
, has recently received a supplementary drug application approval notice issued by the National Medical Products Administration, and its product Cefminox sodium for injection has passed The quality and efficacy consistency evaluation of generic drugs.
Cefminox sodium for injection is an anti-infective drug.
-
Dongyangguang: Application for drug registration of insulin aspart injection has been accepted
Time of Update: 2021-03-27
(hereinafter referred to as "Dongyang Pharmaceutical") insulin aspart injection had received the "Notice of Acceptance" issued by the State Food and Drug Administration.
According to Ai Kunwei data, in 2019, China's diabetes drug sales amount is approximately 3.
-
What is the production capacity of China's antibody drugs? Can the situation of key equipment and materials be broken by import?
Time of Update: 2021-03-27
In recent years, China's antibody drug commercialization production capacity has made considerable progress, but the overall production capacity is insufficient, the production capacity is scattered, the process experience is lacking, the core equipment and materials have not been localized, and the production talent echelon has not yet formed.
-
Central Document: Four New Changes in the Development of Village Clinics
Time of Update: 2021-03-27
Rural revitalization cannot do without the support of rural medical and health services, and the improvement of rural doctors' medical and health services is inseparable The promotion of rural doctors' talent team is inseparable from the expansion and development of village-level medical institutions.
-
The 20 best-performing new drugs in the market in 2020
Time of Update: 2021-03-27
It was first approved for marketing in the United States in December 2019, with sales revenue of US$200 million in the first year.
-
New oral TYK2 inhibitor! Nuocheng Jianhua Class 1 New Drug Clinical Application Accepted
Time of Update: 2021-03-27
SourceGuanlan PharmaceuticalOn February 26, Nuocheng Jianhua announced that its new drug clinical trial application for its new Tyrosine Kinase 2 (TYK2) inhibitor ICP-332 has been accepted by the China National Medical Products Administration (NMPA).
-
2021 AACR | Chinese companies such as BeiGene, Corning Jerry, and Tianjing Bio will make their debut
Time of Update: 2021-03-27
From https://#!/9325/[2] Tianjing Bio will announce the mechanism of action and preclinical research data of its differentiated CD73 antibody Uliledlimab at the 2021 AACR (American Association for Cancer Research) annual meeting.
-
The focus of retail pharmacy inspections is here
Time of Update: 2021-03-27
Retail pharmacies, submit a self-inspection report before the end of NovemberIn accordance with the requirements of the "Plan", the supervision of drug business links will be supervised by each city bureau over the headquarters of drug retail chain enterprises, drug and medical device network sales companies, vaccine distribution companies, and disease prevention and control institutions (the Provincial Center for Disease Control and Prevention is governed by the Hefei Municipal Bureau).
-
New news about essential medicines or increase in the proportion of essential medicines used
Time of Update: 2021-03-27
Medical Network News on March 23 Up-regulation ratio Recently, a circulating document shows that Jiangxi Province has recently adjusted the requirements for the proportion of essential medicines in public medical institutions.
-
Roche withdraws PD-L1 inhibitor Tecentriq for bladder cancer indications in the U.S.
Time of Update: 2021-03-27
As of July 2018, the data detection committee of the IMvigor130 study found that newly-treated locally advanced or metastatic urothelial cancer patients who were not suitable for cisplatin chemotherapy received Tecentriq single-agent first-line treatment, and patients with low PD-L1 expression survived As a result, the FDA has restricted Tecentriq's first-line treatment of bladder cancer as a restriction on the positive expression of PD-L1.
-
CStone's platinib enters China for approval and is expected to usher in the first approved RET inhibitor
Time of Update: 2021-03-27
Public information shows that the indication for this application of the drug is a locally advanced or metastatic non-small cell lung cancer (NSCLC) adult patient who has previously received platinum-containing chemotherapy and has a positive RET gene fusion.
-
Jiangsu Provincial Food and Drug Administration issued notice of Bristol-Myers Squibb's cancellation of drug business license
Time of Update: 2021-03-27
On March 15, the Jiangsu Provincial Food and Drug Administration issued an announcement stating that, in accordance with the "Administrative Licensing Law", "Drug Administration Law", "Drug Distribution License Management Measures" and other relevant regulations, it was approved by Bristol-Myers Squibb (China) Pharmaceutical Co.
-
Yangtze River Health: The State Food and Drug Administration agrees to change the holder of the marketing license for caspofungin acetate for injection
Time of Update: 2021-03-27
On March 18, the Yangtze River Health announced that the State Food and Drug Administration agreed that caspofungin acetate for injection (drug approval number: Sinopharm Zhunzi H202003001, Sinopharm Zhunzi H202003002, specifications 50mg, 70mg) drug marketing license holders "Borui Pharmaceutical (Suzhou) Co.
-
Novo Nordisk launches clinical trials of long-acting insulin in China once a week
Time of Update: 2021-03-27
The latest announcement of the Chinese drug clinical trial registration and information disclosure platform, Novo Nordisk launched a trial in China to study the pharmacokinetic characteristics of icodec insulin in Chinese subjects with type 2 diabetes, aiming to evaluate icodec insulin injections The stay and changes in the patient’s blood over time after administration.
-
Unlicensed pharmacist pharmacy fined 50,000
Time of Update: 2021-03-27
. On March 2, the inspection focus of Shanxi Province's "Notice on Printing and Distributing the Provincial Drug Circulation Supervision and Inspection Work Plan in 2021" also talked about the investigation of illegal behaviors such as non-compliance in the sales of prescription drugs and "certification" of licensed pharmacists.
-
Jinling Pharmaceutical's ferrous succinate tablets obtained the consistency evaluation of the National Food and Drug Administration
Time of Update: 2021-03-27
On March 23, Jinling Pharmaceutical issued an announcement stating that the branch Jinling Pharmaceutical Factory had recently received a notice of acceptance of the consistency evaluation of ferrous succinate tablets issued by the State Food and Drug Administration.
Jinling Pharmaceutical Factory first obtained the Drug Registration Approval for this product in 2002.
